Hepatitis C in pregnancy ICD 10 coding captures a clinically significant scenario where maternal viremia meets perinatal transmission risk. Accurate identification using ICD 10 codes supports surveillance, billing, and care coordination for birthing parents and newborns.
This overview explains how ICD 10 classifies hepatitis C in pregnancy, linking clinical documentation to precise codes and highlighting implications for management and follow-up.
| Clinical Context | ICD 10 Code | Notes for Pregnancy | Impact on Care |
|---|---|---|---|
| Chronic HCV in pregnancy | B17.9 | Use when hepatitis C status is confirmed, regardless of trimester | Guides counseling on transmission risk and postpartum follow-up |
| Acute HCV in pregnancy | B16.2 | Capture new infection during pregnancy or pregnancy-related transfusion | May prompt referral to hepatology and avoidance of ribavirin |
| Perinatal HCV transmission | Z3A. | Not standalone; requires maternal HCV documentation | Triggers neonatal HCV testing algorithm at 1–2 months |
| Code status after delivery | B17.9 or Z86.19 | Z86.19 indicates prior infection; B17.9 if active infection documented postpartum | Influences future antiviral eligibility and liver disease screening |
Maternal Hepatitis C Infection ICD 10 Coding Details
During pregnancy, precise documentation determines whether hepatitis C is classified as chronic, acute, or perinatally transmitted. ICD 10 provides specific codes to distinguish scenarios that affect obstetric decisions, mode of delivery considerations, and infant testing strategies.
Providers must link maternal hepatitis C status clearly in the medical record. When maternal infection is confirmed, B17.9 is often appropriate, while prior resolved infection may be coded with Z86.19, avoiding confusion with active viral replication.
Accurate use of ICD 10 supports quality measures, enables data collection on HCV in pregnancy, and ensures appropriate follow-up plans for both the parent and the newborn after discharge.
Perinatal Transmission Risk and Counseling
Understanding transmission dynamics is central to counseling. Overall vertical transmission risk is roughly 5–6 percent, rising to about 11 percent when the mother is coinfected with HIV, highlighting the importance of comprehensive care.
Mode of delivery does not significantly alter transmission risk in the absence of other indications, so planned cesarean delivery is not routinely recommended solely for hepatitis C status. Providers should instead focus on optimizing maternal health and avoiding procedures that might increase blood exposure during birth.
Breastfeeding is generally considered safe, particularly when nipples are intact and no cracked or bleeding lesions are present, allowing birthing parents to choose feeding goals aligned with their preferences and clinical context.
Newborn Evaluation and Postpartum Testing Algorithm
Infants exposed to hepatitis C require structured follow-up to determine infection status. Unlike some infections, antibody testing in newborns is unreliable because maternal antibodies persist for up to 18 months, necessitating virologic assessment.
The standard approach involves HCV RNA testing at 1–2 months of age, with a repeat test if the result is positive or indeterminate. If the RNA test is negative, no further testing is typically needed, supporting timely reassurance or linkage to care.
Pediatric providers play a crucial role in coordinating these tests, interpreting results in the context of maternal history, and guiding families through the next steps for vaccination, liver health, and linkage to specialists as required.
Antiviral Therapy Considerations During and After Pregnancy
Direct-acting antivirals are highly effective for hepatitis C but are generally deferred until after pregnancy due to limited safety data and potential teratogenicity concerns with older agents like ribavirin.
For pregnant people with advanced liver disease, careful monitoring by a hepatology team can reduce maternal complications. After delivery, individuals with sustained virologic response can be reevaluated for future antiviral regimens, many of which remain compatible with lactation depending on specific medications used.
Postpartum care plans should address not only virologic cure but also mental health, substance use support, and coordination between obstetric, hepatology, and pediatric teams to ensure continuity across the care journey. Follow-up visits can align with well-child visits to simplify scheduling and improve retention.
Key Takeaways for Hepatitis C in Pregnancy ICD 10 Practice
- Use B17.9 for confirmed chronic hepatitis C during pregnancy to streamline referrals and counseling
- Assign B16.2 for acute HCV infection to ensure appropriate obstetric and antiviral planning
- Pair perinatal exposure with maternal hepatitis C codes rather than using Z3A alone
- Schedule infant HCV RNA testing at 1–2 months to accurately assess transmission
- Coordinate care across obstetric, hepatology, and pediatric teams to support maternal and infant health
FAQ
Reader questions
What does the ICD 10 code B17.9 indicate during pregnancy?
B17.9 represents chronic hepatitis C infection when active viral replication is documented. In pregnancy, it signals the need for obstetric and hepatology coordination, maternal-fetal medicine involvement, and structured postpartum follow-up to monitor liver health.
How should acute hepatitis C be coded if diagnosed during pregnancy?
Acute hepatitis C is coded as B16.2. This distinction highlights a recent infection, informs counseling regarding transmission, and typically avoids the use of ribavirin while guiding decisions about timing of antiviral therapy until after delivery.
Is Z3A appropriate to report for perinatal hepatitis C transmission?
Z3A should not be used as a standalone code. It may accompany the maternal B17.9 or B16.2 code only when transmission to the newborn is confirmed or strongly suspected, ensuring clarity in data reporting and clinical tracking.
What follow-up testing is recommended for exposed infants?
Infants exposed to hepatitis C should undergo HCV RNA testing at 1–2 months of age. A positive RNA test confirms infection, while a negative result typically rules out perinatal transmission, allowing for appropriate immunization, growth monitoring, and timely linkage to pediatric specialty care.